Korean Circulation Journal

  • 제54권9호
  • /
  • Pages.545-548
  • /
  • 2024
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Exploring New Combination Strategy of Lipid-Lowering Therapies for Primary Prevention of Cardiovascular Disease

  • Jun Hwan Cho (CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital) ;
  • Eun Jeong Cho (CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital) ;
  • Young-Hoon Jeong (CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital)
  • 투고 : 2024.07.01
  • 심사 : 2024.07.24
  • 발행 : 2024.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Hwang IC, Kim CH, Kim JY, et al. Changes in risk factor status and risk of future ASCVD events in primary prevention. Korean Circ J 2024;54:354-6.
  2. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
  3. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63.
  4. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
  5. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31.
  6. Chou R, Cantor A, Dana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2022;328:754-71.
  7. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 2019;140:992-1003.
  8. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA 2023;330:131-40.
  9. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
  10. Cha JJ, Hong SJ, Lim S, et al. Comparison of statin with ezetimibe combination therapy versus statin monotherapy for primary prevention in middle-aged adults. Korean Circ J 2024;54:534-44.
  11. Jun JE, Jeong IK, Ahn KJ, Chung HY, Hwang YC. Combination of low- or moderate-intensity statin and ezetimibe versus high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study. Eur J Prev Cardiol. 2024 [Epub ahead of print].
  12. Yoon M, Lee CJ, Park S, Lee SH. Statins and clinical outcomes in patients with low to moderate risk but with non-obstructive carotid plaques: the SCOPE-CP study. Korean Circ J 2022;52:890-900.